Advances in neonatal cell therapies: proceedings of the First Neonatal Cell Therapies Symposium (2022)

A Malhotra, B Thebaud, MCB Paton, B Fleiss… - Pediatric …, 2023 - nature.com
Despite considerable advances, there is a need to improve the outcomes of newborn
infants, especially related to prematurity, encephalopathy and other conditions. In principle …

[HTML][HTML] Molecular mechanisms and targets of right ventricular fibrosis in pulmonary hypertension

FT Bekedam, MJ Goumans, HJ Bogaard… - Pharmacology & …, 2023 - Elsevier
Right ventricular fibrosis is a stress response, predominantly mediated by cardiac
fibroblasts. This cell population is sensitive to increased levels of pro-inflammatory …

Role of Nrf2 in lipopolysaccharide‐induced acute kidney injury: protection by human umbilical cord blood mononuclear cells

LX Feng, F Zhao, Q Liu, JC Peng… - Oxidative medicine …, 2020 - Wiley Online Library
Background. Acute kidney injury (AKI) is one of the common complications of sepsis.
Heretofore, there is no effective treatment for septic AKI. Recent studies have revealed that …

Medical therapy for heart failure associated with pulmonary hypertension

JGE Zelt, KR Chaudhary, VJ Cadete… - Circulation …, 2019 - Am Heart Assoc
The past 2 decades have witnessed a> 40% improvement in mortality for patients with heart
failure and left ventricular systolic dysfunction. This success has coincided with the stepwise …

[HTML][HTML] Autologous stem cell therapy for hypoplastic left heart syndrome: safety and feasibility of intraoperative intramyocardial injections

HM Burkhart, MY Qureshi, JW Rossano… - The Journal of thoracic …, 2019 - Elsevier
Objectives Staged surgical palliation for hypoplastic left heart syndrome results in an
increased workload on the right ventricle serving as the systemic ventricle. Concerns for …

Age-dependent effect of pediatric cardiac progenitor cells after juvenile heart failure

U Agarwal, AW Smith, KM French… - Stem cells …, 2016 - academic.oup.com
Children with congenital heart diseases have increased morbidity and mortality, despite
various surgical treatments, therefore warranting better treatment strategies. Here we …

Stem cell therapy for pulmonary arterial hypertension: an update

QW Sun, Z Sun - The Journal of Heart and Lung Transplantation, 2022 - Elsevier
Pulmonary arterial hypertension (PAH) remains a deadly disease, and there currently is no
cure for this life-threating medical problem. The average lifespan is about 5 to 7 years after …

Promising therapeutic approaches in pulmonary arterial hypertension

MK Ali, K Ichimura, E Spiekerkoetter - Current Opinion in Pharmacology, 2021 - Elsevier
Pulmonary arterial hypertension (PAH) is a debilitating multifactorial disease characterized
by progressive pulmonary vascular remodeling, elevated pulmonary arterial pressure, and …

Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats

EG Schmuck, TA Hacker, DA Schreier… - American Journal …, 2019 - journals.physiology.org
Right ventricular failure (RVF) is a common cause of death in patients suffering from
pulmonary arterial hypertension (PAH). The current treatment for PAH only moderately …

Novel therapeutic targets for the treatment of right ventricular remodeling: insights from the pulmonary artery banding model

A Mamazhakypov, N Sommer, B Assmus… - International Journal of …, 2021 - mdpi.com
Right ventricular (RV) function is the main determinant of the outcome of patients with
pulmonary hypertension (PH). RV dysfunction develops gradually and worsens …